More on AGEN
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Net loss | -100.87M |
| Depreciation and amortization | 3.66M |
| Intangible asset impairment | |
| Change in fair value of derivative liability | |
| Share-based compensation | 8.7M |
| Net gain on extinguishment of debt | 0 |
| Non-cash interest expense | |
| Loss on sale of property and equipment | |
| Loss on monetization of receivable | |
| Accounts receivable | -480.83K |
| Inventories | 0 |
| Prepaid expenses | -1.07M |
| Accounts payable | -1.27M |
| Deferred revenue | -3.29M |
| Accrued liabilities and other current liabilities | 6.34M |
| Other operating assets and liabilities | 887.38K |
| Net cash used in operating activities | |
| Proceeds from maturities of available-for-sale securities | |
| Collection of receivable from sale of patent applications | |
| Proceeds from sale of property and equipment | |
| Purchases of available-for-sale securities | |
| Purchases of plant and equipment | -8.19M |
| Net cash (used in) provided by investing activities | |
| Net proceeds from issuance of common stock | |
| Proceeds from exercise of stock options | |
| Payment of long-term debt | |
| Proceeds from employee stock purchases | 1.09M |
| Treasury stock received to satisfy minimum tax withholding requirements | |
| Payment of series A convertible preferred stock dividends | |
| Net cash provided by financing activities | |
| Net (decrease) increase in cash and cash equivalents | -61.26M |
| Cash and cash equivalents, beginning of period | 136.7M |
| Cash and cash equivalents, end of period | 75.44M |
| Convertible Note adjustment to equity for conversion option | |
| Reclassification of derivative liability into equity | |
| Issuance of senior secured convertible notes as payment in-kind for interest | |
| Issuance of common stock, $0.01 par value, as payment of long-term debt including accrued and unpaid interest | |
Entities mentioned with AGEN
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
